Top

Published in:

Open Access 01-12-2021 | Cancer Immunotherapy | Review

Recent advances in cancer immunotherapy

Authors: Qiang Sun, Gerry Melino, Ivano Amelio, Jingting Jiang, Ying Wang, Yufang Shi

Published in: Discover Oncology | Issue 1/2021

Abstract

Cancer immunotherapy represents a major advance in the cure of cancer following the dramatic advancements in the development and refinement of chemotherapies and radiotherapies. In the recent decades, together with the development of early diagnostic techniques, immunotherapy has significantly contributed to improving the survival of cancer patients. The immune-checkpoint blockade agents have been proven effective in a significant fraction of standard therapy refractory patients. Importantly, recent advances are providing alternative immunotherapeutic tools that could help overcome their limitations. In this mini review, we provide an overview on the main steps of the discovery of classic immune-checkpoint blockade agents and summarise the most recent development of novel immunotherapeutic strategies, such as tumour antigens, bispecific antibodies and TCR-engineered T cells.

Yanagi Y, Yoshikai Y, Leggett K, Clark SP, Aleksander I, Mak TW. A human T cell-specific cDNA clone encodes a protein having extensive homology to immunoglobulin chains. Nature. 1984;308(5955):145–9.PubMedCrossRef

Mak TW. From the T-cell receptor to cancer therapy: an interview with Tak W. Mak Cell Death Differ. 2021;28(1):5–14.PubMedCrossRef

Hedrick SM, Nielsen EA, Kavaler J, Cohen DI, Davis MM. Sequence relationships between putative T-cell receptor polypeptides and immunoglobulins. Nature. 1984;308(5955):153–8.PubMedCrossRef

Hedrick SM, Cohen DI, Nielsen EA, Davis MM. Isolation of cDNA clones encoding T cell-specific membrane-associated proteins. Nature. 1984;308(5955):149–53.PubMedCrossRef

Mak TW. The T cell antigen receptor: “The Hunting of the Snark.” Eur J Immunol. 2007;37(Suppl 1):S83-93.PubMedCrossRef

Davis MM, Boniface JJ, Reich Z, Lyons D, Hampl J, Arden B, Chien Y. Ligand recognition by alpha beta T cell receptors. Annu Rev Immunol. 1998;16:523–44.PubMedCrossRef

Newell EW, Davis MM. Beyond model antigens: high-dimensional methods for the analysis of antigen-specific T cells. Nat Biotechnol. 2014;32(2):149–57.PubMedPubMedCentralCrossRef

Toyonaga B, Mak TW. Genes of the T-cell antigen receptor in normal and malignant T cells. Annu Rev Immunol. 1987;5:585–620.PubMedCrossRef

Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H, Mak TW. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995;270(5238):985–8.PubMedCrossRef

10.

Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734–6.PubMedCrossRef

11.

Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321–30.CrossRefPubMed

12.

Shi YF, Sahai BM, Green DR. Cyclosporin A inhibits activation-induced cell death in T-cell hybridomas and thymocytes. Nature. 1989;339(6226):625–6.PubMedCrossRef

13.

Ashwell JD, Cunningham RE, Noguchi PD, Hernandez D. Cell growth cycle block of T cell hybridomas upon activation with antigen. J Exp Med. 1987;165(1):173–94.PubMedCrossRef

14.

Palacios R, Karasuyama H, Rolink A. Ly1+ PRO-B lymphocyte clones. Phenotype, growth requirements and differentiation in vitro and in vivo. EMBO J. 1987;6(12):3687–93.PubMedPubMedCentralCrossRef

15.

Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11(11):3887–95.PubMedPubMedCentralCrossRef

16.

Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16(5):275–87.PubMedPubMedCentralCrossRef

17.

Gupta RG, Li F, Roszik J, Lizee G. Exploiting tumor neoantigens to target cancer evolution: current challenges and promising therapeutic approaches. Cancer Discov. 2021;11(5):1024–39.PubMedCrossRefPubMedCentral

18.

Messmer MN, Snyder AG, Oberst A. Comparing the effects of different cell death programs in tumor progression and immunotherapy. Cell Death Differ. 2019;26(1):115–29.PubMedCrossRef

19.

Oktay K, Santaliz-Casiano A, Patel M, Marino N, Storniolo AMV, Torun H, Acar B, Madak Erdogan Z. A computational statistics approach to evaluate blood biomarkers for breast cancer risk stratification. Horm Cancer. 2020;11(1):17–33.PubMedCrossRef

20.

Celardo I, Melino G, Amelio I. Commensal microbes and p53 in cancer progression. Biol Direct. 2020;15(1):25.PubMedPubMedCentralCrossRef

21.

Larmuseau M, Verbeke LPC, Marchal K. Associating expression and genomic data using co-occurrence measures. Biol Direct. 2019;14(1):10.PubMedPubMedCentralCrossRef

22.

Khairi S, Osborne J, Jacobs MF, Clines GT, Miller BS, Hughes DT, Else T. Outcome of clinical genetic testing in patients with features suggestive for hereditary predisposition to PTH-mediated hypercalcemia. Horm Cancer. 2020;11(5–6):250–5.PubMedCrossRefPubMedCentral

23.

Hsiue EH, Wright KM, Douglass J, Hwang MS, Mog BJ, Pearlman AH, Paul S, DiNapoli SR, Konig MF, Wang Q, et al. Targeting a neoantigen derived from a common TP53 mutation. Science. 2021;371:6533.CrossRef

24.

Douglass J, Hsiue EH, Mog BJ, Hwang MS, DiNapoli SR, Pearlman AH, Miller MS, Wright KM, Azurmendi PA, Wang Q, et al. Bispecific antibodies targeting mutant RAS neoantigens. Sci Immunol. 2021;6(57):5515.CrossRef

25.

Paul S, Pearlman AH, Douglass J, Mog BJ, Hsiue EH, Hwang MS, DiNapoli SR, Konig MF, Brown PA, Wright KM, et al. TCR beta chain-directed bispecific antibodies for the treatment of T cell cancers. Sci Transl Med. 2021;13:584.CrossRef

26.

Panchin AY, Aleoshin VV, Panchin YV. From tumors to species: a SCANDAL hypothesis. Biol Direct. 2019;14(1):3.PubMedPubMedCentralCrossRef

27.

Mihaylov I, Kandula M, Krachunov M, Vassilev D. A novel framework for horizontal and vertical data integration in cancer studies with application to survival time prediction models. Biol Direct. 2019;14(1):22.PubMedPubMedCentralCrossRef

28.

Levine AJ. p53: 800 million years of evolution and 40 years of discovery. Nat Rev Cancer. 2020;20(8):471–80.PubMedCrossRef

29.

Drosten M, Barbacid M. Targeting the MAPK Pathway in KRAS-Driven Tumors. Cancer Cell. 2020;37(4):543–50.PubMedCrossRef

30.

Mantovani F, Collavin L, Del Sal G. Mutant p53 as a guardian of the cancer cell. Cell Death Differ. 2019;26(2):199–212.PubMedCrossRef

31.

Ham SW, Jeon HY, Jin X, Kim EJ, Kim JK, Shin YJ, Lee Y, Kim SH, Lee SY, Seo S, et al. TP53 gain-of-function mutation promotes inflammation in glioblastoma. Cell Death Differ. 2019;26(3):409–25.PubMedCrossRef

32.

Pitolli C, Wang Y, Mancini M, Shi Y, Melino G, Amelio I. Do Mutations Turn p53 into an Oncogene? Int J Mol Sci. 2019;20(24):6241.PubMedCentralCrossRef

33.

Pitolli C, Wang Y, Candi E, Shi Y, Melino G, Amelio I. p53-mediated tumor suppression: DNA-damage response and alternative mechanisms. Cancers (Basel). 2019;11(12):1983.CrossRef

34.

Amelio I, Mancini M, Petrova V, Cairns RA, Vikhreva P, Nicolai S, Marini A, Antonov AA, Le Quesne J, Baena Acevedo JD, et al. p53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression. Proc Natl Acad Sci USA. 2018;115(46):E10869–78.PubMedPubMedCentralCrossRef

35.

Kim SY, Nair DM, Romero M, Serna VA, Koleske AJ, Woodruff TK, Kurita T. Transient inhibition of p53 homologs protects ovarian function from two distinct apoptotic pathways triggered by anticancer therapies. Cell Death Differ. 2019;26(3):502–15.PubMedCrossRef

36.

Li Y, Cao Y, Xiao J, Shang J, Tan Q, Ping F, Huang W, Wu F, Zhang H, Zhang X. Inhibitor of apoptosis-stimulating protein of p53 inhibits ferroptosis and alleviates intestinal ischemia/reperfusion-induced acute lung injury. Cell Death Differ. 2020;27(9):2635–50.PubMedCrossRefPubMedCentral

37.

Li X, Guo M, Cai L, Du T, Liu Y, Ding HF, Wang H, Zhang J, Chen X, Yan C. Competitive ubiquitination activates the tumor suppressor p53. Cell Death Differ. 2020;27(6):1807–18.PubMedCrossRef

38.

Liu H, Weng W, Guo R, Zhou J, Xue J, Zhong S, Cheng J, Zhu MX, Pan SJ, Li Y. Olig2 SUMOylation protects against genotoxic damage response by antagonizing p53 gene targeting. Cell Death Differ. 2020;27(11):3146–61.PubMedPubMedCentralCrossRef

39.

Liang J, Niu Z, Zhang B, Yu X, Zheng Y, Wang C, Ren H, Wang M, Ruan B, Qin H, et al. p53-dependent elimination of aneuploid mitotic offspring by entosis. Cell Death Differ. 2021;28(2):799–813.PubMedCrossRef

40.

Huang S, Li Y, Yuan X, Zhao M, Wang J, Li Y, Li Y, Lin H, Zhang Q, Wang W, et al. The UbL-UBA Ubiquilin4 protein functions as a tumor suppressor in gastric cancer by p53-dependent and p53-independent regulation of p21. Cell Death Differ. 2019;26(3):516–30.PubMedCrossRef

41.

Lonetto G, Koifman G, Silberman A, Attery A, Solomon H, Levin-Zaidman S, Goldfinger N, Porat Z, Erez A, Rotter V. Mutant p53-dependent mitochondrial metabolic alterations in a mesenchymal stem cell-based model of progressive malignancy. Cell Death Differ. 2019;26(9):1566–81.PubMedCrossRef

42.

Espinoza JA, Zisi A, Kanellis DC, Carreras-Puigvert J, Henriksson M, Huhn D, Watanabe K, Helleday T, Lindstrom MS, Bartek J. The antimalarial drug amodiaquine stabilizes p53 through ribosome biogenesis stress, independently of its autophagy-inhibitory activity. Cell Death Differ. 2020;27(2):773–89.PubMedCrossRef

43.

Nepravishta R, Sabelli R, Iorio E, Micheli L, Paci M, Melino S. Oxidative species and S-glutathionyl conjugates in the apoptosis induction by allyl thiosulfate. FEBS J. 2012;279(1):154–67.PubMedCrossRef

44.

Angelucci S, Sacchetta P, Moio P, Melino S, Petruzzelli R, Gervasi P, Di Ilio C. Purification and characterization of glutathione transferases from the sea bass (Dicentrarchus labrax) liver. Arch Biochem Biophys. 2000;373(2):435–41.PubMedCrossRef

45.

Pallucca R, Visconti S, Camoni L, Cesareni G, Melino S, Panni S, Torreri P, Aducci P. Specificity of epsilon and non-epsilon isoforms of arabidopsis 14–3–3 proteins towards the H+-ATPase and other targets. PLoS ONE. 2014;9(6):e90764.PubMedPubMedCentralCrossRef

46.

Mauretti A, Neri A, Kossover O, Seliktar D, Nardo PD, Melino S. Design of a novel composite H2 S-releasing hydrogel for cardiac tissue repair. Macromol Biosci. 2016;16(6):847–58.PubMedCrossRef

47.

Amelio I, Melino G. The p53 family and the hypoxia-inducible factors (HIFs): determinants of cancer progression. Trends Biochem Sci. 2015;40(8):425–34.PubMedCrossRef

48.

Dobon B, Montanucci L, Pereto J, Bertranpetit J, Laayouni H. Gene connectivity and enzyme evolution in the human metabolic network. Biol Direct. 2019;14(1):17.PubMedPubMedCentralCrossRef

49.

Kawulok J, Kawulok M, Deorowicz S. Environmental metagenome classification for constructing a microbiome fingerprint. Biol Direct. 2019;14(1):20.PubMedPubMedCentralCrossRef

50.

Caputo A, Fournier PE, Raoult D. Genome and pan-genome analysis to classify emerging bacteria. Biol Direct. 2019;14(1):5.PubMedPubMedCentralCrossRef

51.

Walker AR, Datta S. Identification of city specific important bacterial signature for the MetaSUB CAMDA challenge microbiome data. Biol Direct. 2019;14(1):11.PubMedPubMedCentralCrossRef

52.

Bellomaria A, Barbato G, Melino G, Paci M, Melino S. Recognition of p63 by the E3 ligase ITCH: effect of an ectodermal dysplasia mutant. Cell Cycle. 2010;9(18):3730–9.PubMedCrossRef

53.

Lena AM, Cipollone R, Amelio I, Catani MV, Ramadan S, Browne G, Melino G, Candi E. Skn-1a/Oct-11 and DeltaNp63alpha exert antagonizing effects on human keratin expression. Biochem Biophys Res Commun. 2010;401(4):568–73.PubMedCrossRef

54.

Nemajerova A, Amelio I, Gebel J, Dotsch V, Melino G, Moll UM. Non-oncogenic roles of TAp73: from multiciliogenesis to metabolism. Cell Death Differ. 2018;25(1):144–53.PubMedCrossRef

55.

Amelio I, Antonov AA, Catani MV, Massoud R, Bernassola F, Knight RA, Melino G, Rufini A. TAp73 promotes anabolism. Oncotarget. 2014;5(24):12820–934.PubMedPubMedCentralCrossRef

56.

Amelio I, Cutruzzola F, Antonov A, Agostini M, Melino G. Serine and glycine metabolism in cancer. Trends Biochem Sci. 2014;39(4):191–8.PubMedPubMedCentralCrossRef

57.

Bellomaria A, Barbato G, Melino G, Paci M, Melino S. Recognition mechanism of p63 by the E3 ligase Itch: novel strategy in the study and inhibition of this interaction. Cell Cycle. 2012;11(19):3638–48.PubMedPubMedCentralCrossRef

58.

Vikhreva P, Melino G, Amelio I. p73 Alternative Splicing: Exploring a Biological Role for the C-Terminal Isoforms. J Mol Biol. 2018;430(13):1829–38.PubMedPubMedCentralCrossRef

59.

Grespi F, Amelio I, Tucci P, Annicchiarico-Petruzzelli M, Melino G. Tissue-specific expression of p73 C-terminal isoforms in mice. Cell Cycle. 2012;11(23):4474–83.PubMedPubMedCentralCrossRef

60.

Liu L, Wang G, Wang L, Yu C, Li M, Song S, Hao L, Ma L, Zhang Z. Computational identification and characterization of glioma candidate biomarkers through multi-omics integrative profiling. Biol Direct. 2020;15(1):10.PubMedPubMedCentralCrossRef

61.

Chierici M, Francescatto M, Bussola N, Jurman G, Furlanello C. Predictability of drug-induced liver injury by machine learning. Biol Direct. 2020;15(1):3.PubMedPubMedCentralCrossRef

62.

Gallo M, Paludi D, Cicero DO, Chiovitti K, Millo E, Salis A, Damonte G, Corsaro A, Thellung S, Schettini G, et al. Identification of a conserved N-capping box important for the structural autonomy of the prion alpha 3-helix: the disease associated D202N mutation destabilizes the helical conformation. Int J Immunopathol Pharmacol. 2005;18(1):95–112.PubMedCrossRef

63.

Han Y, Ye X, Wang C, Liu Y, Zhang S, Feng W, Huang K, Zhang J. Integration of molecular features with clinical information for predicting outcomes for neuroblastoma patients. Biol Direct. 2019;14(1):16.PubMedPubMedCentralCrossRef

64.

Han Y, Ye X, Cheng J, Zhang S, Feng W, Han Z, Zhang J, Huang K. Integrative analysis based on survival associated co-expression gene modules for predicting Neuroblastoma patients’ survival time. Biol Direct. 2019;14(1):4.PubMedPubMedCentralCrossRef

65.

Dao T, Pankov D, Scott A, Korontsvit T, Zakhaleva V, Xu Y, Xiang J, Yan S, de Morais Guerreiro MD, Veomett N, et al. Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. Nat Biotechnol. 2015;33(10):1079–86.PubMedPubMedCentralCrossRef

66.

Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer. 2016;16(9):566–81.PubMedPubMedCentralCrossRef

67.

Chowdhury S, Beitel LK, Lumbroso R, Purisima EO, Paliouras M, Trifiro M. A targeted bivalent androgen receptor binding compound for prostate cancer therapy. Horm Cancer. 2019;10(1):24–35.PubMedCrossRef

68.

Lim SM, Pyo KH, Soo RA, Cho BC. The promise of bispecific antibodies: Clinical applications and challenges. Cancer Treat Rev. 2021;99:102240.PubMedCrossRef

69.

MacDonald L, Jenkins J, Purvis G, Lee J, Franco AT. The thyroid tumor microenvironment: potential targets for therapeutic intervention and prognostication. Horm Cancer. 2020;11(5–6):205–17.PubMedCrossRefPubMedCentral

70.

Garrido F. HLA Class-I expression and cancer immunotherapy. Adv Exp Med Biol. 2019;1151:79–90.PubMedCrossRef

71.

Hou AJ, Chen LC, Chen YY. Navigating CAR-T cells through the solid-tumour microenvironment. Nat Rev Drug Discov. 2021;20(7):531–50.PubMedCrossRef

72.

DePeaux K, Delgoffe GM. Metabolic barriers to cancer immunotherapy. Nat Rev Immunol. 2021. https://doi.org/10.1038/s41577-021-00541-y.CrossRefPubMed

73.

Wang L, Liu Y, Du T, Yang H, Lei L, Guo M, Ding HF, Zhang J, Wang H, Chen X, et al. ATF3 promotes erastin-induced ferroptosis by suppressing system Xc. Cell Death Differ. 2020;27(2):662–75.PubMedCrossRef

74.

Vance JE. Inter-organelle membrane contact sites: implications for lipid metabolism. Biol Direct. 2020;15(1):24.PubMedPubMedCentralCrossRef

75.

Casimiro-Soriguer CS, Loucera C, Perez Florido J, Lopez-Lopez D, Dopazo J. Antibiotic resistance and metabolic profiles as functional biomarkers that accurately predict the geographic origin of city metagenomics samples. Biol Direct. 2019;14(1):15.PubMedPubMedCentralCrossRef

76.

Lee PMY, Kwok CH, Chan WC, Wu C, Tsang KH, Law SH, Yeung YC, Wang F, Yang XR, Tse LA. Heterogeneous associations between obesity and reproductive-related factors and specific breast cancer subtypes among hong kong chinese women. Horm Cancer. 2020;11(3–4):191–9.PubMedPubMedCentralCrossRef

77.

Licht JD, Bennett RL. Leveraging epigenetics to enhance the efficacy of immunotherapy. Clin Epigenetics. 2021;13(1):115.PubMedPubMedCentralCrossRef

78.

Sumsion GR, Bradshaw MS 3rd, Beales JT, Ford E, Caryotakis GRG, Garrett DJ, LeBaron ED, Nwosu IO, Piccolo SR. Diverse approaches to predicting drug-induced liver injury using gene-expression profiles. Biol Direct. 2020;15(1):1.PubMedPubMedCentralCrossRef

79.

Li KP, Ladle BH, Kurtulus S, Sholl A, Shanmuganad S, Hildeman DA. T-cell receptor signal strength and epigenetic control of Bim predict memory CD8(+) T-cell fate. Cell Death Differ. 2020;27(4):1214–24.PubMedCrossRef

80.

Jing YY, Cai FF, Zhang L, Han J, Yang L, Tang F, Li YB, Chang JF, Sun F, Yang XM, et al. Epigenetic regulation of the Warburg effect by H2B monoubiquitination. Cell Death Differ. 2020;27(5):1660–76.PubMedCrossRef

81.

Nazio F, Bordi M, Cianfanelli V, Locatelli F, Cecconi F. Autophagy and cancer stem cells: molecular mechanisms and therapeutic applications. Cell Death Differ. 2019;26(4):690–702.PubMedPubMedCentralCrossRef

82.

Maiuri MC, Kroemer G. Therapeutic modulation of autophagy: which disease comes first? Cell Death Differ. 2019;26(4):680–9.PubMedPubMedCentralCrossRef

83.

Germic N, Frangez Z, Yousefi S, Simon HU. Regulation of the innate immune system by autophagy: monocytes, macrophages, dendritic cells and antigen presentation. Cell Death Differ. 2019;26(4):715–27.PubMedPubMedCentralCrossRef

84.

Germic N, Frangez Z, Yousefi S, Simon HU. Regulation of the innate immune system by autophagy: neutrophils, eosinophils, mast cells NK cells. Cell Death Differ. 2019;26(4):703–14.PubMedPubMedCentralCrossRef

85.

Seton-Rogers S. Eliminating protective autophagy in KRAS-mutant cancers. Nat Rev Cancer. 2019;19(5):247.PubMedCrossRef

86.

Willson J. Mitosis flips the switch on autophagy control. Nat Rev Mol Cell Biol. 2020;21(1):4–5.PubMedCrossRef

87.

Ozten N, Vega K, Liehr J, Huang X, Horton L, Cavalieri EL, Rogan EG, Bosland MC. Role of estrogen in androgen-induced prostate carcinogenesis in NBL rats. Horm Cancer. 2019;10(2–3):77–88.PubMedPubMedCentralCrossRef

88.

Fowler AM, Salem K, DeGrave M, Ong IM, Rassman S, Powers GL, Kumar M, Michel CJ, Mahajan AM. Progesterone receptor gene variants in metastatic estrogen receptor positive breast cancer. Horm Cancer. 2020;11(2):63–75.PubMedPubMedCentralCrossRef

89.

Del Moral-Morales A, Gonzalez-Orozco JC, Capetillo-Velazquez JM, Pina-Medina AG, Camacho-Arroyo I. The role of mPRdelta and mPRepsilon in human glioblastoma cells: expression, hormonal regulation, and possible clinical outcome. Horm Cancer. 2020;11(2):117–27.PubMedCrossRef

90.

Li X, Zhang H, Zhou Y, Cheng R. Risk factors for central lymph node metastasis in the cervical region in papillary thyroid carcinoma: a retrospective study. World J Surg Oncol. 2021;19(1):138.PubMedPubMedCentralCrossRef

91.

Santoro A, Mele E, Marino M, Viggiano A, Nori SL, Meccariello R. The complex interplay between endocannabinoid system and the estrogen system in central nervous system and periphery. Int J Mol Sci. 2021;22(2):972.PubMedPubMedCentralCrossRef

92.

Davis PJ, Mousa SA, Schechter GP, Lin HY. Platelet ATP, thyroid hormone receptor on integrin alphavbeta3 and cancer metastasis. Horm Cancer. 2020;11(1):13–6.PubMedCrossRef

93.

Sepich-Poore GD, Zitvogel L, Straussman R, Hasty J, Wargo JA, Knight R. The microbiome and human cancer. Science. 2021;371:6536.CrossRef

94.

Lennon JT, Locey KJ. More support for Earth’s massive microbiome. Biol Direct. 2020;15(1):5.PubMedPubMedCentralCrossRef

95.

Zhu C, Miller M, Lusskin N, Mahlich Y, Wang Y, Zeng Z, Bromberg Y. Fingerprinting cities: differentiating subway microbiome functionality. Biol Direct. 2019;14(1):19.PubMedPubMedCentralCrossRef

96.

Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA. 1993;90(2):720–4.PubMedPubMedCentralCrossRef

97.

Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA. 1989;86(24):10024–8.PubMedPubMedCentralCrossRef

98.

D’Aloia MM, Zizzari IG, Sacchetti B, Pierelli L, Alimandi M. CAR-T cells: the long and winding road to solid tumors. Cell Death Dis. 2018;9(3):282.PubMedPubMedCentralCrossRef

99.

Melero I, Castanon E, Alvarez M, Champiat S, Marabelle A. Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nat Rev Clin Oncol. 2021. https://doi.org/10.1038/s41571-021-00507-y.CrossRefPubMedPubMedCentral

100.

Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2021. https://doi.org/10.1038/s41577-021-00547-6.CrossRefPubMedPubMedCentral

101.

Zhang Z, Jiang D, Yang H, He Z, Liu X, Qin W, Li L, Wang C, Li Y, Li H, et al. Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor. Cell Death Dis. 2019;10(7):476.PubMedPubMedCentralCrossRef

102.

Nagarsheth NB, Norberg SM, Sinkoe AL, Adhikary S, Meyer TJ, Lack JB, Warner AC, Schweitzer C, Doran SL, Korrapati S, et al. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. Nat Med. 2021;27(3):419–25.PubMedCrossRef

103.

Murata K, Nakatsugawa M, Rahman MA, Nguyen LT, Millar DG, Mulder DT, Sugata K, Saijo H, Matsunaga Y, Kagoya Y, et al. Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma. Elife. 2020;9:1.CrossRef

104.

Sugata K, Matsunaga Y, Yamashita Y, Nakatsugawa M, Guo T, Halabelian L, Ohashi Y, Saso K, Rahman MA, Anczurowski M, et al. Affinity-matured HLA class II dimers for robust staining of antigen-specific CD4(+) T cells. Nat Biotechnol. 2021;39(8):958–67.PubMedCrossRef

105.

Rahman MA, Murata K, Burt BD, Hirano N. Changing the landscape of tumor immunology: novel tools to examine T cell specificity. Curr Opin Immunol. 2021;69:1–9.PubMedCrossRef

106.

Qu Q, Li Y, Fang X, Zhang L, Xue C, Ge X, Wang X, Jiang Y. Differentially expressed tRFs in CD5 positive relapsed & refractory diffuse large B cell lymphoma and the bioinformatic analysis for their potential clinical use. Biol Direct. 2019;14(1):23.PubMedPubMedCentralCrossRef

107.

Ryan FJ. Application of machine learning techniques for creating urban microbial fingerprints. Biol Direct. 2019;14(1):13.PubMedPubMedCentralCrossRef

108.

Harris ZN, Dhungel E, Mosior M, Ahn TH. Massive metagenomic data analysis using abundance-based machine learning. Biol Direct. 2019;14(1):12.PubMedPubMedCentralCrossRef

Title: Recent advances in cancer immunotherapy
Authors: Qiang Sun
Gerry Melino
Ivano Amelio
Jingting Jiang
Ying Wang
Yufang Shi
Publication date: 01-12-2021
Publisher: Springer US
Keyword: Cancer Immunotherapy
Published in: Discover Oncology / Issue 1/2021
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-021-00422-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Caffeic acid phenethyl ester (CAPE) confers wild type p53 function in p53Y220C mutant: bioinformatics and experimental evidence

Extracellular vesicle-derived miR-320a targets ZC3H12B to inhibit tumorigenesis, invasion, and angiogenesis in ovarian cancer

The prognostic significance of primary tumor size in squamous cell carcinoma of the penis

FAM65A as a novel prognostic biomarker in human tumors reveal by a pan-cancer analysis

Silencing long intergenic non-protein coding RNA 00987 inhibits proliferation, migration, and invasion of osteosarcoma cells by sponging miR-376a-5p to regulate FNBP1 expression

microRNA-26a represses pancreatic cancer cell malignant behaviors by targeting E2F7

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials